A prospective study of 2,570 IFN-ß-treated MS patients revealed that an early start within the first years after diagnosis significantly lowered the risk of EDSS progression and long term disability (milestone: EDSS 4) (34). This evidence concerns the gene IFNA1 and myeloid sarcoma.